debt_leverage_profile
0.89x Total Debt / Equity (Moderate leverage)
High
SEC-XBRL
interest_rate_sensitivity
Moderate-high; AYTU carries variable-rate debt and has historically operated cash-flow negative, so a 200bps rise meaningfully increases burn rate and refinancing risk.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Active pharmaceutical ingredients sourced predominantly from India and China; FDA import alert or export restriction at either node would disrupt generic/branded product supply.
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; virtually no sovereign currency devaluation exposure as AYTU derives nearly all revenue from U.S. commercial operations.
Inferred
Agent_Inference
geographic_footprint
Essentially U.S.-only commercial footprint; negligible foreign-currency revenue exposure across all markets.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single-source API suppliers for several branded products (e.g., Adzenys XR-ODT formulation technology) likely exceed 30% of COGS for that product line; high substitution risk.
Inferred
Agent_Inference
business_model_type_primary
Specialty pharmaceutical commercial-stage company; cloud disruption would impair CRM and back-office but not core drug distribution—operational impact moderate, not existential.
Inferred
Agent_Inference
business_model_type_secondary
Secondary model is licensing/royalty on out-licensed assets; cloud termination has minimal direct impact on royalty collection.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; commercial operations rely on standard pharma ERP/CRM (SAP, Salesforce) with readily available alternatives; no proprietary API lock-in detected.
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is prescription drug sales—clearly a regulated product sale, not an investment contract. Howey Test inapplicable.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate HIPAA exposure from patient data in co-pay and adherence programs; CCPA exposure limited; GDPR immaterial given negligible EU operations.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; AYTU holds sub-5% share in ADHD market; no dominant market position or predatory pricing allegations noted.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional (pharmacy prescription fills); multi-year contracts with PBMs provide partial revenue visibility but represent minority of revenue. ~80% transactional.
Inferred
Agent_Inference
monetization_vector
Primary monetization via wholesale drug sales to distributors (McKesson, AmerisourceBergen, Cardinal Health); secondary via patient co-pay programs and managed care rebates.
Inferred
Agent_Inference
pricing_architecture
WAC-based pricing with mandatory rebates to PBMs and Medicaid; significant gross-to-net erosion (~50-60%); price increases constrained by formulary placement negotiations.
Inferred
Agent_Inference
pricing_power_rating
Weak; generic competition in ADHD space and PBM leverage compress net pricing; limited ability to raise WAC without formulary exclusion risk.
Inferred
Agent_Inference
target_gross_margin_bracket
69.0% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider problem; prescriptions require physician order and pharmacy dispensing. Churn risk is physician switching to generic alternatives—moderate and rising.
Inferred
Agent_Inference
headcount_cost_structure
Headcount-linear for sales force expansion; doubling revenue in specialty pharma requires proportional field sales rep additions; limited operational leverage in current model.
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost of growth; incremental prescription volume requires incremental detailing, sampling, and managed care investment—unfavorable unit economics at scale.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; AYTU does not operate a franchise network.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, physician detailing costs become prohibitive without blockbuster revenue; CAC per prescriber estimated $8,000-$15,000 annually; economics compress at scale without pipeline diversification.
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; prescription drug adoption is driven by clinical evidence and sales force reach, not user-base scale.
Inferred
Agent_Inference
asset_efficiency_ratio
-11.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; ADHD medications are chronic-use products with high refill rates, but patient cost sensitivity and insurance coverage loss during recessions reduce adherence.
Inferred
Agent_Inference
customer_segment_primary
Pediatric and adult ADHD patients (via prescribing physicians); concentrated in primary care and psychiatry specialties; top-3 wholesalers represent ~90% of direct purchase volume.
Inferred
Agent_Inference
customer_segment_secondary
Managed care organizations and PBMs (Express Scripts, CVS Caremark) as formulary gatekeepers; loss of preferred formulary status at one major PBM materially impairs revenue.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.3% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001385818
High
SEC-EDGAR
ticker
AYTU
High
SEC-EDGAR